Pluristem Announces Effectiveness of the Exclusive License Agreement to Develop

patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Reply New Message

Prev Message Back To Forum Threaded View Next Message

emit

Rank: Vice President [?]

Points: 41186 [?]

Votes: 199 Score: 3.0 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Pluristem Announces Effectiveness of the Exclusive License Agreement to Develop

posted on Aug 03, 2011 02:56PM

Pluristem Announces Effectiveness of the Exclusive License Agreement to Develop and Commercialize PLX Cells for the Treatment of Pulmonary Hypertension

HAIFA, Israel, Aug. 3, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI - News) (TASE:PLTR) today announced that following the consent of the Office of the Chief Scientist of Israel, Pluristem's exclusive out-license agreement signed on June 19, 2011 with United Therapeutics Corporation for the use of Pluristem's PLacental eXpanded (PLX) cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension (PH) has become effective as of August 2, 2011.''

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply